Vasiliki Michalarea
Overview
Explore the profile of Vasiliki Michalarea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mostaghim A, Minkove S, Aguilar-Company J, Ruiz-Camps I, Eremiev-Eremiev S, Dettorre G, et al.
Int J Infect Dis
. 2023 Nov;
139:13-20.
PMID: 38029831
Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19. Methods: The OnCovid registry (NCT04393974) was...
2.
Li S, Sharma B, Yusuf S, Michalarea V, Gleeson M, Hickmott L, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Sep;
24(1):48-54.
PMID: 37734988
Background: Treatment with CHOP-based chemotherapy with consolidative radiotherapy (CRT) for primary mediastinal B cell lymphoma (PMBCL) has been the standard approach in the pre-rituximab era. Overtreatment with CRT for patients...
3.
Banerjee S, Michalarea V, Ang J, Ingles Garces A, Biondo A, Funingana I, et al.
Clin Cancer Res
. 2022 Aug;
28(21):4634-4641.
PMID: 35984704
Purpose: CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus is selectively taken up by α-FR-overexpressing tumors. Patients And Methods: A 3+3...
4.
Russell B, Moss C, Tsotra E, Gousis C, Josephs D, Enting D, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053432
Background: This study aimed to assess the outcome of cancer patients undergoing systemic anti-cancer treatment (SACT) at our centre to help inform future clinical decision-making around SACT during the COVID-19...
5.
Carotenuto P, Amato F, Lampis A, Rae C, Hedayat S, Previdi M, et al.
Nat Commun
. 2021 Nov;
12(1):6738.
PMID: 34795259
FOLFIRINOX, a combination of chemotherapy drugs (Fluorouracil, Oxaliplatin, Irinotecan -FOI), provides the best clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients. In this study we explore the role of miRNAs...
6.
Yap T, Kristeleit R, Michalarea V, Pettitt S, Lim J, Carreira S, et al.
Cancer Discov
. 2020 Jun;
10(10):1528-1543.
PMID: 32532747
Preclinical studies have demonstrated synergy between PARP and PI3K/AKT pathway inhibitors in and (-deficient and -proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective intrapatient dose- escalation...
7.
de Bono J, Lin C, Chen L, Corral J, Michalarea V, Rihawi K, et al.
Br J Cancer
. 2020 Mar;
122(9):1324-1332.
PMID: 32161368
Background: Xentuzumab, an insulin-like growth factor (IGF)-1/IGF-2-neutralising antibody, binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling. Two first-in-human trials assessed the maximum-tolerated/relevant biological dose (MTD/RBD), safety, pharmacokinetics, pharmacodynamics, and activity...
8.
Carotenuto P, Hedayat S, Fassan M, Cardinale V, Lampis A, Guzzardo V, et al.
Hepatology
. 2019 Dec;
72(3):982-996.
PMID: 31879968
Background And Aims: Changes in single microRNA (miRNA) expression have been associated with chemo-resistance in biliary tract cancers (BTCs). However, a global assessment of the dynamic role of the microRNome...
9.
Salati M, Caputo F, Cunningham D, Marcheselli L, Spallanzani A, Rimini M, et al.
Eur J Cancer
. 2019 Jul;
117:84-90.
PMID: 31276980
Background: Chemotherapy is the mainstay treatment for advanced biliary cancer (ABC). Best supportive care and clinical trials are currently alternative options. The identification of a prognostic score that can be...
10.
Michalarea V, Fontana E, Ingles Garces A, Williams A, Smyth E, Picchia S, et al.
Curr Probl Cancer
. 2019 Mar;
43(5):487-494.
PMID: 30827742
Gastrointestinal cancers are very common cancers with colorectal being the fourth most common type, gastric the sixth, and esophageal the tenth. Although recent advances have been made in management including...